Humoral immune responses to gag and env proteins from human immunodeficiency virus type 1 in hemophiliac patients

Am J Hematol. 1991 Jan;36(1):35-41. doi: 10.1002/ajh.2830360108.

Abstract

Solid-phase enzyme immunoassays using recombinant gag and env proteins were developed to study humoral immune responses to HIV infection in a cohort of 105 hemophiliac patients. Thirteen patients with ARC or AIDS and 92 asymptomatic patients were studied. A cross-sectional study showed a wide range of antibody responses to gag and env proteins; however, the differences between the ARC/AIDS and asymptomatic patients were statistically significant for both antigens (P less than .0004). In a longitudinal study, antibody levels in sera from 11 asymptomatic patients with gag antibody log units less than or equal to 1.5 were compared to levels in sera from 10 ARC/AIDS patients and 8 asymptomatic patients with gag antibody greater than 1.5. These patient groups were followed for comparable periods of time (67.1-71.7 mo). The asymptomatic patients with low gag antibody and the ARC/AIDS patients showed a similar pattern of antibody response to gag protein overtime. In hemophiliac patients with HIV-1 infection a low titer of antibody to gag protein is not invariably associated with clinical deterioration and is not a useful serologic marker of impending progression to AIDS.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS-Related Complex / immunology
  • Acquired Immunodeficiency Syndrome / immunology
  • Antibodies, Viral / analysis
  • Antibody Formation
  • Cross-Sectional Studies
  • Gene Products, env / immunology*
  • Gene Products, gag / immunology*
  • HIV Seropositivity / immunology
  • HIV-1 / metabolism*
  • Hemophilia A / immunology*
  • Humans
  • Immunoenzyme Techniques
  • Longitudinal Studies
  • Male

Substances

  • Antibodies, Viral
  • Gene Products, env
  • Gene Products, gag